Feds subpoena Merck on marketing of hepatitis, cancer drugs

Merck said it received a subpoena related to marketing and selling activities with respect to three drugs: Temodar, PegIntron and Intron A.

The subpoena, disclosed today in a regulatory filing, requests information related to the company's promotional activities from January 1, 2004, to the present, in “a federal healthcare investigation under criminal statutes.”

The company said it is cooperating with the Department of Justice investigation.

Global sales of Temodar, a treatment for brain tumors, were $1.07 billion in 2010. PegIntron, for treating hepatitis C, generated $737 million last year, while Intron A, marketed for chronic hepatitis B and C and numerous anticancer indications, had $209 million in 2010 sales.

You must be a registered member of MMM to post a comment.

Next Article in Channel


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.